18 min listen
Targeting prostacyclin to inhibit platelet activation; MRD-tailored myeloma maintenance; AREG and HSC function in DNA damage repair deficiency and agi…
FromBlood Podcast
Targeting prostacyclin to inhibit platelet activation; MRD-tailored myeloma maintenance; AREG and HSC function in DNA damage repair deficiency and agi…
FromBlood Podcast
ratings:
Length:
20 minutes
Released:
Nov 2, 2023
Format:
Podcast episode
Description
In this week's episode we'll see how targeting the prostacyclin receptor is a promising strategy for regulating hemostasis and thrombosis. Then, we'll learn how new evidence indicates that the progression rate is low in MRD-negative myeloma patients who discontinue post-transplant lenalidomide and dexamethasone maintenance therapy after 2 years. Finally we'll discuss how amphiregulin from leptin receptor-positive niche cells in the bone marrow mediates crosstalk between the niche and hematopoietic stem cells under conditions of DNA repair deficiency and aging.
Released:
Nov 2, 2023
Format:
Podcast episode
Titles in the series (100)
Sneak Peek Episode 4: The topics in this episode include studies on the mechanism of progression in myelodysplastic syndromes, the value of gait speed as a predictor of outcomes in older adults with hematologic malignancies, the role of extended eltrombobag therapy on severe a by Blood Podcast